References in periodicals archive ?
A statement released by the Endocrine Society after the FDA announcement was made says that the FDA's recent efforts are "a reasonable step to ensuring the safety of patients taking L-T4 [levothyroxine sodium]," but urged the agency to do more.
As of January 2007, four branded oral L-T4 products were available in the United States: levothyroxine sodium (Unithroid, Levoxyl, Synthroid and Levothroid).
Generally, you should stick with one L-T4 product for treating hypothyroidism, generally a branded L-T4.
Bioavailability of L-T4 was reduced by 40% regardless of whether subjects took the drug shortly before or immediately after the meal.
In clinical terms, this means that taking rapid-release L-T4 in proximity to a meal or a medication known to interfere with L-T4 renders a 100-mcg dose of Levoxyl equivalent to a 60-mcg dose.
As of January 2005, seven branded orally administered L-T4 products have been approved by the U.
In general, one should stay with a single L-T4 product for treatment of hypothyroidism, which is possible by staying with a branded L-T4.
In other words, patients who have been lax about taking their L-T4 separate from meals may require a dose correction of up to 40% of administered drug in order to optimize therapy, he said.
The L-T4 dose was reduced to 50 [micro]g/day and TFT results were maintained within reference intervals.
TSH lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients.
Therefore, the bone marrow-absorbed dose after treatment with RAI would be expected to be lower for patients given rhTSH, which is protective for hypothyroidism and additionally may reduce the half-life of RAI, than for patients subjected to L-T4 withdrawal (12-14).